Abstract
Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC)3 cytosine deaminase activity have been found in over half of cancer types, including some therapy-resistant and metastatic tumors. Driver mutations can occur in APOBEC3-favored sequence contexts, suggesting that mutagenesis by APOBEC3 enzymes may drive cancer evolution. The APOBEC3-mediated signatures are often detected in subclonal branches of tumor phylogenies and are acquired in cancer cell lines over long periods of time, indicating that APOBEC3 mutagenesis can be ongoing in cancer. Collectively, these and other observations have led to the proposal that APOBEC3 mutagenesis represents a disease-modifying process that could be inhibited to limit tumor heterogeneity, metastasis and drug resistance. However, critical aspects of APOBEC3 biology in cancer and in healthy tissues have not been clearly defined, limiting well-grounded predictions regarding the benefits of inhibiting APOBEC3 mutagenesis in different settings in cancer. We discuss the relevant mechanistic gaps and strategies to address them to investigate whether inhibiting APOBEC3 mutagenesis may confer clinical benefits in cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
No new data were generated for this text.
References
Harris, R. S. & Dudley, J. P. APOBECs and virus restriction. Virology 479-480, 131–145 (2015).
Petljak, M. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature 607, 799–807 (2022).
Petljak, M. & Maciejowski, J. Molecular origins of APOBEC-associated mutations in cancer. DNA Repair 94, 102905 (2020).
Green, A. M. & Weitzman, M. D. The spectrum of APOBEC3 activity: from anti-viral agents to anti-cancer opportunities. DNA Repair 83, 102700 (2019).
Granadillo Rodríguez, M., Flath, B. & Chelico, L. The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead. Open Biol. 10, 200188 (2020).
Mas-Ponte, D. & Supek, F. DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. Nat. Genet. 52, 958–968 (2020).
Bergstrom, E. N. et al. Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature 602, 510–517 (2022).
Roberts, S. A. et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 46, 424–435 (2012).
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979–993 (2012).
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science 376, abl9283 (2022).
DeWeerd, R. A. et al. Prospectively defined patterns of APOBEC3A mutagenesis are prevalent in human cancers. Cell Rep. 38, 110555 (2022).
Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247–1253 (2002).
Hultquist, J. F. et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 85, 11220–11234 (2011).
Olson, M. E., Harris, R. S. & Harki, D. A. APOBEC enzymes as targets for virus and cancer therapy. Cell Chem. Biol. 25, 36–49 (2018).
Venkatesan, S. et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. Ann. Oncol. 29, 563–572 (2018).
Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704–712 (2015).
Law, E. K. et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci. Adv. 2, e1601737 (2016).
Kvach, M. V. et al. Inhibiting APOBEC3 activity with single-stranded DNA containing 2′-deoxyzebularine analogues. Biochemistry 58, 391–400 (2019).
Barzak, F. M. et al. Selective inhibition of APOBEC3 enzymes by single-stranded DNAs containing 2′-deoxyzebularine. Org. Biomol. Chem. 17, 9435–9441 (2019).
Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366–370 (2013).
Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977–983 (2013).
Harris, R. S. Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Res. 17, 8 (2015).
Kuong, K. J. & Loeb, L. A. APOBEC3B mutagenesis in cancer. Nat. Genet. 45, 964–965 (2013).
Olson, M. E. et al. Oxidative reactivities of 2-furylquinolines: ubiquitous scaffolds in common high-throughput screening libraries. J. Med. Chem. 58, 7419–7430 (2015).
Leonard, B. et al. The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res. 75, 4538–4547 (2015).
Kanu, N. et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 17, 185 (2016).
Isozaki, H. et al. APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer. Preprint at bioRxiv https://doi.org/10.1101/2021.01.20.426852 (2021).
Caswell, D. R. et al. The role of APOBEC3B in lung tumour evolution and targeted therapy resistance. Preprint at bioRxiv https://doi.org/10.1101/2020.12.18.423280 (2022).
Chan, K. et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 47, 1067–1072 (2015).
Langenbucher, A. et al. An extended APOBEC3A mutation signature in cancer. Nat. Commun. 12, 1602 (2021).
Buisson, R. et al. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science 364, eaaw2872 (2019).
Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
Cortez, L. M. et al. APOBEC3A is a prominent cytidine deaminase in breast cancer. PLoS Genet. 15, e1008545 (2019).
Starrett, G. J. et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat. Commun. 7, 12918 (2016).
Jalili, P. et al. Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nat. Commun. 11, 2971 (2020).
Petljak, M. et al. Characterizing mutational signatures in human cancer cell lines reveals episodic APOBEC mutagenesis. Cell 176, 1282–1294 (2019).
Covino, D. A., Gauzzi, M. C. & Fantuzzi, L. Understanding the regulation of APOBEC3 expression: current evidence and much to learn. J. Leukoc. Biol. 103, 433–444 (2018).
Xiao, X. et al. Structural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulation. Nucleic Acids Res. 45, 7494–7506 (2017).
Taylor, B. J. et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2, e00534 (2013).
Volkova, N. V. et al. Mutational signatures are jointly shaped by DNA damage and repair. Nat. Commun. 11, 2169 (2020).
Jarvis, M. C. et al. Mutational impact of APOBEC3B and APOBEC3A in a human cell line. Preprint at bioRxiv https://doi.org/10.1101/2022.04.26.489523 (2022).
Kidd, J. M., Newman, T. L., Tuzun, E., Kaul, R. & Eichler, E. E. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3, e63 (2007).
Nik-Zainal, S. et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 46, 487–491 (2014).
Long, J. et al. A common deletion in the APOBEC3 genes and breast cancer risk. J. Natl Cancer Inst. 105, 573–579 (2013).
Middlebrooks, C. D. et al. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. Nat. Genet. 48, 1330–1338 (2016).
Law, E. K. et al. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J. Exp. Med. 217, e20200261 (2020).
Letouzé, E. et al. Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nat. Commun. 8, 1315 (2017).
Kingston, B. et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat. Commun. 12, 2423 (2021).
Barroso-Sousa, R. et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol. 31, 387–394 (2020).
de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
Roper, N. et al. APOBEC mutagenesis and copy-number alterations are drivers of proteogenomic tumor evolution and heterogeneity in metastatic thoracic tumors. Cell Rep. 26, 2651–2666 (2019).
Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep. 7, 1833–1841 (2014).
Glaser, A. P. et al. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. Oncotarget 9, 4537–4548 (2018).
Cannataro, V. L., Mandell, J. D. & Townsend, J. P. Attribution of cancer origins to endogenous, exogenous, and preventable mutational processes. Mol. Biol. Evol. 39, msac084 (2022).
Conticello, S. G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 9, 229 (2008).
Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020).
Moore, L. et al. The mutational landscape of normal human endometrial epithelium. Nature 580, 640–646 (2020).
Li, R. et al. A body map of somatic mutagenesis in morphologically normal human tissues. Nature 597, 398–403 (2021).
Morganella, S. et al. The topography of mutational processes in breast cancer genomes. Nat. Commun. 7, 11383 (2016).
Vöhringer, H., Van Hoeck, A., Cuppen, E. & Gerstung, M. Learning mutational signatures and their multidimensional genomic properties with TensorSignatures. Nat. Commun. 12, 3628 (2021).
Venkatesan, S. et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 11, 2456–2473 (2021).
Wörmann, S. M. et al. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Nat. Cancer 2, 1338–1356 (2021).
Periyasamy, M. et al. APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer. Cell Rep. 13, 108–121 (2015).
Sieuwerts, A. M. et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm. Cancer 5, 405–413 (2014).
Lee, J.-K. et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 35, 3065–3074 (2017).
Yoshida, K. et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature 578, 266–272 (2020).
Oh, S. et al. Genotoxic stress and viral infection induce transient expression of APOBEC3A and pro-inflammatory genes through two distinct pathways. Nat. Commun. 12, 4917 (2021).
Warren, C. J., Westrich, J. A., Van Doorslaer, K. & Pyeon, D. Roles of APOBEC3A and APOBEC3B in human papillomavirus infection and disease progression. Viruses 9, 233 (2017).
Starrett, G. J. et al. Polyomavirus T antigen induces APOBEC3B expression using an LXCXE-dependent and TP53-independent mechanism. mBio 10, e02690-18 (2019).
Hoopes, J. I. et al. APOBEC3A and APOBEC3B preferentially deaminate the lagging strand template during DNA replication. Cell Rep. 14, 1273–1282 (2016).
Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking in human cancer. Science 354, 618–622 (2016).
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
Koning, F. A. et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83, 9474–9485 (2009).
Refsland, E. W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274–4284 (2010).
Ng, J. C. F., Quist, J., Grigoriadis, A., Malim, M. H. & Fraternali, F. Pan-cancer transcriptomic analysis dissects immune and proliferative functions of APOBEC3 cytidine deaminases. Nucleic Acids Res. 47, 1178–1194 (2019).
Periyasamy, M. et al. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. Nucleic Acids Res. 45, 11056–11069 (2017).
Menendez, D., Nguyen, T.-A., Snipe, J. & Resnick, M. A. The cytidine deaminase APOBEC3 family is subject to transcriptional regulation by p53. Mol. Cancer Res. 15, 735–743 (2017).
Periyasamy, M. et al. Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB. Oncogene 40, 1077–1090 (2021).
Lackey, L. et al. APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419, 301–314 (2012).
Lackey, L., Law, E. K., Brown, W. L. & Harris, R. S. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12, 762–772 (2013).
Haradhvala, N. J. et al. Mutational strand asymmetries in cancer genomes reveal mechanisms of DNA damage and repair. Cell 164, 538–549 (2016).
Seplyarskiy, V. B. et al. APOBEC-induced mutations in human cancers are strongly enriched on the lagging DNA strand during replication. Genome Res. 26, 174–182 (2016).
Sakofsky, C. J. et al. Break-induced replication is a source of mutation clusters underlying kataegis. Cell Rep. 7, 1640–1648 (2014).
Chan, K. & Gordenin, D. A. Clusters of multiple mutations: incidence and molecular mechanisms. Annu. Rev. Genet. 49, 243–267 (2015).
Green, A. M. et al. APOBEC3A damages the cellular genome during DNA replication. Cell Cycle 15, 998–1008 (2016).
Maciejowski, J. et al. APOBEC3-dependent kataegis and TREX1-driven chromothripsis during telomere crisis. Nat. Genet. 52, 884–890 (2020).
Brown, A. L. et al. Single-stranded DNA binding proteins influence APOBEC3A substrate preference. Sci. Rep. 11, 21008 (2021).
Green, A. M. et al. Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity. EMBO Rep. 22, e52145 (2021).
Malim, M. H. & Bieniasz, P. D. HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2, a006940 (2012).
Cheng, A. Z. et al. Epstein–Barr virus BORF2 inhibits cellular APOBEC3B to preserve viral genome integrity. Nat. Microbiol. 4, 78–88 (2019).
McLaughlin, R. N. Jr, Gable, J. T., Wittkopp, C. J., Emerman, M. & Malik, H. S. Conservation and innovation of APOBEC3A restriction functions during primate evolution. Mol. Biol. Evol. 33, 1889–1901 (2016).
Sawyer, S. L., Emerman, M. & Malik, H. S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2, E275 (2004).
Zhang, J. & Webb, D. M. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 13, 1785–1791 (2004).
Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).
Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803–809 (2003).
Esnault, C. et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433, 430–433 (2005).
Salter, J. D., Bennett, R. P. & Smith, H. C. The APOBEC protein family: united by structure, divergent in function. Trends Biochem. Sci. 41, 578–594 (2016).
Okeoma, C. M., Lovsin, N., Peterlin, B. M. & Ross, S. R. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445, 927–930 (2007).
Mikl, M. C. et al. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell. Biol. 25, 7270–7277 (2005).
Xuan, D. et al. APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis 34, 2240–2243 (2013).
Komatsu, A., Nagasaki, K., Fujimori, M., Amano, J. & Miki, Y. Identification of novel deletion polymorphisms in breast cancer. Int. J. Oncol. 33, 261–270 (2008).
Gansmo, L. B. et al. APOBEC3A/B deletion polymorphism and cancer risk. Carcinogenesis 39, 118–124 (2018).
Klonowska, K. et al. The 30 kb deletion in the APOBEC3 cluster decreases APOBEC3A and APOBEC3B expression and creates a transcriptionally active hybrid gene but does not associate with breast cancer in the European population. Oncotarget 8, 76357–76374 (2017).
Caval, V., Suspène, R., Shapira, M., Vartanian, J.-P. & Wain-Hobson, S. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damage. Nat. Commun. 5, 5129 (2014).
Wang, S., Jia, M., He, Z. & Liu, X.-S. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene 37, 3924–3936 (2018).
Driscoll, C. B. et al. APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat. Commun. 11, 790 (2020).
Green, A. M. et al. Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint. Cancer Res. 77, 4579–4588 (2017).
Buisson, R., Lawrence, M. S., Benes, C. H. & Zou, L. APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition. Cancer Res. 77, 4567–4578 (2017).
Mehta, K. P. M., Lovejoy, C. A., Zhao, R., Heintzman, D. R. & Cortez, D. HMCES maintains replication fork progression and prevents double-strand breaks in response to APOBEC deamination and abasic site formation. Cell Rep. 31, 107705 (2020).
Biayna, J. et al. Loss of the abasic site sensor HMCES is synthetic lethal with the activity of the APOBEC3A cytosine deaminase in cancer cells. PLoS Biol. 19, e3001176 (2021).
Acknowledgements
M.P.’s research was supported by the European Molecular Biology Organization Long-Term Fellowship (ALTF 760–2019) and is supported by the National Cancer Institute (NCI) (CA270102). J.M.’s laboratory is supported by the NCI (CA212290, CA008748, CA261183, CA270102), the Pew Charitable Trusts, the V Foundation, the Starr Cancer Consortium, the Emerald Foundation and the Geoffrey Beene and Ludwig Centers at the MSKCC. A.M.G.’s laboratory is supported by the NCI (K08CA21299), the Department of Defense (CA2000867), the American Cancer Society, the Cancer Research Foundation and the Children’s Discovery Institute. Research on APOBEC enzymes in the laboratory of M.D.W. was supported by grants from the National Institutes of Health (CA181259 and CA185799). We thank M. O’Reilly and E. Berg from the Broad Institute’s Pattern team for figure graphics.
Author information
Authors and Affiliations
Contributions
All authors contributed to the writing of the paper.
Corresponding author
Ethics declarations
Competing interests
M.P. is a shareholder in Vertex Pharmaceuticals and a compensated consultant through GLG Network. J.M. has received consulting fees from Ono Pharmaceutical. J.M.’s spouse is an employee of and has equity in Bristol Myers Squibb. M.P. and J.M. are inventors of the patent application entitled ‘Tracking APOBEC mutational signatures in tumor cells’ (patent pending). The remaining authors declare no competing interests.
Peer review
Peer review information
Nature Genetics thanks Tim Fenton, Andre Nussenzweig, and Vladimir Seplyarskiy for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Petljak, M., Green, A.M., Maciejowski, J. et al. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer. Nat Genet 54, 1599–1608 (2022). https://doi.org/10.1038/s41588-022-01196-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-022-01196-8